Letrozole (brand name Femara) is an aromatase-inhibitor hormone treatment used mainly for hormone-sensitive breast cancer after menopause. The cancer setting, reproductive status and treatment goal determine how it is used; fertility treatment follows a separate specialist plan. NHS: letrozole overview.
- Hormone-receptor results help determine whether endocrine treatment is relevant. NCI: breast-cancer biomarkers.
- Bone health, blood pressure and cholesterol need planned monitoring. NHS: letrozole monitoring and treatment changes.
- Do not stop, double doses or arrange treatment breaks without the appropriate prescribing advice. NHS: taking and stopping letrozole.
- Ovulation induction is a distinct, monitored unlicensed use in the reviewed UK service. CUH: monitored letrozole ovulation induction.
- Sudden chest pain, stroke symptoms or a severe allergic reaction requires immediate emergency help. NHS: letrozole adverse effects.
- English prescription-item counts do not measure unique patients, cancer-only use or effectiveness. NHSBSA: 2025/26 chemical-substance table.
Table of contents
- Evidence summary
- What letrozole is: prescription tablets, cancer uses and the Femara name
- How it works: aromatase, estrogen and hormone-receptor testing
- Treatment pathways and monitoring: before or after surgery and advanced disease
- Supplements and daily support: bone nutrition, fatigue and eating problems
- What is established and uncertain: licensed care, trial sponsorship and prevention claims
- Risks and urgent symptoms: joint pain, hot flushes and emergency warning signs
- Interactions: HRT, menopause products and tamoxifen sequencing
- Who needs extra assessment: menstrual status, organ disease, pregnancy and fertility use
- Clinician-led use: tablet handling, missed doses and follow-up
- Animal and laboratory evidence: mechanisms and reproductive hazards have limits
- Funding and source roles
- Frequently asked questions
- Sources and funding notes
Evidence summary
Clinical descriptions, care guidance and independently established treatment outcomes have different evidentiary roles. The table identifies what the reviewed sources can support and which financial or clinical questions remain unresolved.
| Question / approach | Evidence reviewed | Funding / conflicts | Interpretation / limits |
|---|---|---|---|
| Hormone-sensitive breast-cancer use | Attributed clinical/label context | Original efficacy finance not fully cleared | Eligibility and care purpose matter. |
| BIG 1-98 outcomes | Original randomized trial inspected | Novartis financed and supplied drugs | Excluded from independent efficacy verdict. |
| Bone and metabolic monitoring | Clinical safety context | Page/contributor allocations unclosed | Individual scan and risk-factor plan. |
| Ovulation induction | Dated UK provider context | Contributor/trial finance unclosed | Unlicensed monitored use; no home protocol. |
| England prescribing frequency | Official community item counts | Public-authority finance disclosed | Not global demand, patients or efficacy. |
| Complementary products | Safety context | No cleared product trial | No treatment replacement established. |
What letrozole is: prescription tablets, cancer uses and the Femara name
Femara is a brand name for letrozole. This prescription tablet belongs to endocrine, or hormone, therapy and is often given after primary breast-cancer treatment such as surgery. Ask whether your prescription is intended to reduce recurrence risk, treat current disease or serve another specialist purpose. NHS: letrozole overview.
The US summary describes postmenopausal breast-cancer uses including adjuvant care for hormone-receptor-positive early disease, extended care after tamoxifen and selected advanced disease. A listed indication does not mean every breast-cancer subtype is eligible. The prescription and local licensing context need to match the actual diagnosis. NCI: letrozole drug summary.
The official England 2025/26 chemical-substance table records 1,277,559 letrozole prescription items. This supports prioritizing a useful medicine guide, not calling it the world’s most popular cancer drug. Items can repeat for the same person and do not identify the treatment indication. NHSBSA: 2025/26 chemical-substance table.
PCA covers community dispensing in England, including some prescriptions issued by hospitals and then dispensed in the community. Medicines dispensed within hospital pharmacies are excluded. This setting matters when comparing an oral medicine with treatments commonly supplied in hospital. NHSBSA: June 2026 PCA methodology.
How it works: aromatase, estrogen and hormone-receptor testing
Letrozole temporarily blocks the activity of aromatase, an enzyme involved in estrogen production. Reducing estrogen can limit the hormone stimulus for estrogen-dependent cancer cells. It is a different treatment class from cytotoxic chemotherapy; a mechanism does not by itself predict an individual response. NCI: letrozole drug summary.
Tumor tissue is tested for estrogen receptors (ER), progesterone receptors (PR) and other features such as HER2. Hormone-receptor-positive and HER2-positive are different descriptions and can overlap. Receptor status can change when cancer returns, so repeat testing may be considered. Ask the team which result supports the endocrine-treatment plan. NCI: breast-cancer biomarkers.
Aromatase inhibitors are mainly used after menopause. For premenopausal breast-cancer care, they can be used with suppression of ovarian function; taking the tablet alone is not an interchangeable plan. NCI also describes GnRH-agonist treatment alongside aromatase inhibitors in men with advanced breast cancer. These are specialist decisions, not instructions to add another hormone medicine. NCI: breast-cancer hormone therapy.
Treatment pathways and monitoring: before or after surgery and advanced disease
Hormone therapy may be given before surgery to treat a hormone-sensitive tumor, after primary treatment to reduce recurrence risk, or for recurrent or advanced disease. These aims require different assessments. Ask what the current phase is intended to achieve and how the team will review progress. NCI: hormone treatment and follow-up.
Selected hormone-receptor-positive breast cancers are treated with hormone therapy plus a targeted medicine, such as a CDK4/6 inhibitor. The exact combination depends on the tumor and care setting. A companion drug has its own adverse effects and monitoring requirements; a letrozole-only leaflet cannot cover the whole combination. NCI: breast-cancer targeted therapy.
Letrozole can weaken bones. Discuss bone-density tests, blood pressure and cholesterol checks with your team, including any protective treatment. Ask who reviews results and when. NHS: letrozole monitoring and treatment changes.
Keep a written record of your treatment goal, start date, pathology results and planned monitoring. At review, discuss missed tablets, symptoms that limit activity and practical difficulty collecting prescriptions. Confirm which service renews the medicine and who is responsible for following up an abnormal result.
Supplements and daily support: bone nutrition, fatigue and eating problems
Bone care considers fracture risk, prior injuries and other factors as well as a scan result. The clinician can assess dietary calcium and vitamin D and whether supplementation is needed. Nutrition support and prescribed bone treatment have different roles; a supplement should not be assumed to replace a fracture-prevention plan. NHS: osteoporosis assessment and nutrition.
Fatigue during cancer care can have several contributing causes, including treatment, poor sleep, pain, anemia or infection. Tell the team when tiredness limits normal activities or persists despite rest. A tailored assessment can guide support and suitable activity; attributing every change to letrozole may miss another problem. NCI: fatigue assessment.
Both weight gain and declining intake can occur during cancer care. Discuss a meaningful change with the team or dietitian rather than beginning a restrictive diet to counter it. The appropriate response depends on symptoms, nutrition and the cause; weight change alone does not show whether cancer treatment is working. NCI: weight and eating problems.
No complementary product replaces prescribed letrozole or establishes an anticancer cure here. Discuss supplements and herbs before adding them, particularly products marketed for menopause symptoms. Correcting a nutritional need is separate from proving cancer control, and a natural label does not establish compatibility with treatment. NCCIH: cancer and complementary approaches.
What is established and uncertain: licensed care, trial sponsorship and prevention claims
BIG 1-98 was a randomized comparison in postmenopausal, hormone-receptor-positive early breast cancer. Its original report states that Novartis financed the trial and supplied study drugs, while IBCSG coordinated it. The report’s data-access statements and methods do not remove that maker relationship; its efficacy results are excluded from this article’s independent verdict. BIG 1-98: 2011 original trial and funding.
Preventing recurrence after a breast-cancer diagnosis differs from reducing the chance of a first cancer. NCI’s December 2025 prevention page states that aromatase inhibitors are not FDA-approved for primary breast-cancer risk reduction. Do not turn a general prevention statement into a personal or worldwide letrozole recommendation. NCI: breast-cancer primary prevention.
A trial may examine a medicine, combination or treatment timing under specific eligibility and consent requirements. Research participation cannot promise benefit. Ask how an offered trial differs from usual care, which sponsor pays for it, what extra visits it requires and which outcomes it is designed to measure. NCI: clinical-trial participation.
Clinical use, regulatory labeling and independence grading answer different questions. The reviewed public pages describe care pathways; their underlying efficacy studies are not financially cleared merely because a public institution hosts the explanation. This guide gives no independent ranking of letrozole against anastrozole, exemestane or tamoxifen.
Risks and urgent symptoms: joint pain, hot flushes and emergency warning signs
Hot flushes, sleep difficulty, fatigue, low mood and muscle or joint aches can occur. Discuss troublesome effects and new vaginal bleeding. Seek urgent medical advice now for sudden joint pain, jaundice, fever or a painful swollen limb. Sudden chest pain, stroke symptoms or severe swelling/breathing trouble suggesting allergy requires immediate emergency help. Do not drive yourself to emergency care. NHS: letrozole adverse effects.
Lower estrogen during hormone treatment can contribute to vaginal dryness or discomfort. Ask about suitable lubricants or moisturizers and sexual-health support. Any hormonal vaginal product needs an oncology discussion; a general menopause recommendation does not establish suitability during treatment. Sexual symptoms are legitimate care concerns rather than something you must silently endure. NCI: sexual health during cancer care.
When reporting a symptom, explain when it began, whether it is worsening, which medicines you take and how it affects walking, sleep or eating. Emergency symptoms should go directly to emergency services; a routine appointment, online message or side-effect diary should not delay assessment.
Interactions: HRT, menopause products and tamoxifen sequencing
NHS cautions against combining letrozole with hormone-replacement therapy or menopause supplements that may interfere with its cancer-treatment purpose. Other herbs and complementary products are not reliably established as safe combinations. Give the pharmacist the complete list of prescription medicines, nonprescription products and supplements, including anything you plan to start. NHS: letrozole interactions.
The dated maker label reports that concurrent tamoxifen reduces letrozole exposure. A planned sequence after tamoxifen is different from taking both together. Ask the prescriber to confirm any changeover. Novartis: dated Femara prescribing label.
Check the active ingredients in a menopause remedy rather than relying on its packaging. If another clinician suggests a hormone preparation, explain that you take letrozole and ask the services to coordinate. A broad interaction summary cannot replace a review of your entire combination, medical conditions and current product leaflet.
Who needs extra assessment: menstrual status, organ disease, pregnancy and fertility use
Before prescribing, discuss allergies, whether periods continue or return, serious liver or kidney disease and fragile bones. These details can change the assessment or monitoring plan. They should not be used to copy a modified tablet schedule from the internet; the specialist must interpret them within the actual cancer or fertility setting. NHS: letrozole suitability.
Letrozole is not recommended during pregnancy or breastfeeding in the NHS cancer-medicine information. Contact the prescriber urgently if pregnancy is possible, and ask about appropriate contraception when relevant. A fertility prescription has a different purpose and requires its own specialist instructions; it is not permission to continue cancer treatment through pregnancy. NHS: letrozole and reproduction.
The US maker label contraindicates pregnancy and warns that severe liver impairment can increase exposure. Reproductive precautions and any dose modification require prescribing assessment. Novartis: dated Femara prescribing label.
Cambridge IVF describes ovulation induction as unlicensed and requires monitoring. This fertility programme is separate from a cancer prescription. Use the fertility service’s instructions for eligibility, treatment timing and pregnancy-related checks. CUH: monitored letrozole ovulation induction.
Clinician-led use: tablet handling, missed doses and follow-up
Follow the dispensing label and your specialist’s directions. NHS describes swallowing the tablet whole with water, with or without food, and not crushing or chewing it. If swallowing is difficult, ask the pharmacist about an appropriate formulation. Never double a dose to replace a missed one; use the supplied missed-dose instructions. Seek urgent medical advice if an extra dose leaves you unwell, and keep the packet available. NHS: taking and stopping letrozole.
For troublesome side effects, ask the specialist about alternatives or an agreed break. Do not arrange a break yourself; tolerance and the treatment plan vary. NHS: letrozole monitoring and treatment changes.
Breast-cancer follow-up can include clinical examination, mammography when applicable and other tests selected by the team. Ask what is being checked for disease follow-up and what is being checked for medicine toxicity. There is no single universal monitoring calendar for every letrozole prescription. NCI: hormone treatment and follow-up.
Confirm your intended course and review date, how to handle a missed tablet or accidental extra dose, and which symptoms require urgent contact. Keep the packet and current medicine list available if seeking help. Do not transfer a fertility cycle, another patient’s duration or a combination-drug schedule to your own prescription.
Animal and laboratory evidence: mechanisms and reproductive hazards have limits
Laboratory or animal findings can explain a pathway or suggest a safety concern, but they cannot establish an effective personal cancer or fertility regimen. Human research needs an appropriate population, safety monitoring and meaningful clinical outcomes. A change in estrogen, a cell response or an animal result cannot substitute for that assessment. NCI: research phases.
Animal reproductive toxicity appears in the maker label. It supports a safety warning, not a human fertility schedule or individual risk estimate. Novartis: dated Femara prescribing label.
Ask whether a claim concerns an enzyme, tumor response, recurrence, survival or quality of life, and whether the compared population matches your situation. Funding and method quality are separate judgments. A study can use strong randomized methods while still failing this site’s independence requirement because the medicine’s maker financed it.
Funding and source roles
Research funding at a glance
34 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
The source-specific map separates documented institutional funding from disease-page payments and trial sponsorship. Unknown allocations remain unknown. A public agency, charity or academic address does not by itself establish independent treatment efficacy.
| Source | Funding / backers | Country / jurisdiction | Independence | Credibility / incentives / gaps |
|---|---|---|---|---|
| NHS: letrozole overview | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | C provisional. Reviewed 24 November 2023; next review November 2026. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: letrozole suitability | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | C provisional. Reviewed 24 November 2023; next review November 2026. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: taking and stopping letrozole | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | C provisional. Reviewed 24 November 2023; next review November 2026. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: letrozole adverse effects | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | C provisional. Reviewed 24 November 2023; next review November 2026. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: letrozole and reproduction | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | C provisional. Reviewed 24 November 2023; next review November 2026. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: letrozole interactions | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | C provisional. Reviewed 24 November 2023; next review November 2026. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: letrozole monitoring and treatment changes | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | C provisional. Reviewed 24 November 2023; next review November 2026. Public-service and institutional incentives; no independently cleared product outcome. |
| NHS: osteoporosis assessment and nutrition | See the dated national NHS policy below; page, contributor and original-study finance remain unclosed. | England, United Kingdom; national NHS website | Tier 2 — clinical context; provisional | C provisional. Reviewed 13 October 2022; October 2025 review overdue. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: letrozole drug summary | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 13 December 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: breast-cancer hormone therapy | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 23 September 2026. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: breast-cancer biomarkers | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Posted 2 December 2025. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: breast-cancer targeted therapy | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Posted 2 December 2025. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: breast-cancer primary prevention | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 2 December 2025. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: hormone treatment and follow-up | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Reviewed 15 May 2025. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: sexual health during cancer care | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Reviewed 29 December 2022. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: fatigue assessment | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 20 September 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: weight and eating problems | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 15 October 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: clinical-trial participation | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 3 November 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| NCI: research phases | See NCI budget, gifts and editorial disclosures below; page, expert and trial allocations remain unclosed. | United States; NCI, Bethesda, Maryland | Tier 2 — clinical context; provisional | C provisional. Updated 8 November 2024. Public-service and institutional incentives; no independently cleared product outcome. |
| CUH: monitored letrozole ovulation induction | See CUH’s own accounts below. Exact leaflet allocation, contributor contracts and cited fertility-trial sponsorship unclosed. | United Kingdom; Cambridge IVF/CUH, Cambridge | Tier 2 — provider clinical context; provisional | C provisional. Approved 2 June 2025, version 1. Provider/research interests; no independent comparative fertility result. |
| Novartis: dated Femara prescribing label | Maker-issued Novartis Pharmaceuticals Corporation label; Swiss parent routes below. Medicine sales interests; DailyMed hosting does not establish independence. | United States; East Hanover, New Jersey; Swiss parent, Basel | Tier 4 — manufacturer-produced label; self-interest | D for independent efficacy. Posted 11 June 2026, prescribing text revised December 2024. Regulatory safety context retained. |
| BIG 1-98: 2011 original trial and funding | Novartis financed/supplied drugs; IBCSG coordinated. Other IBCSG support: NCI CA-75362; Swedish Cancer Society; Cancer Council Australia; Australian New Zealand Breast Cancer Trials Group; Frontier Science and Technology Research Foundation; SAKK; Cancer Research Switzerland/Oncosuisse; OSKK. Authors disclose company fees, research and stock; current receipts unclosed. | Multinational trial; Novartis, Basel, Switzerland; lead Regan, Dana-Farber/Boston, United States | Tier 4 — manufacturer-financed/supplied trial; self-interest | D for independent efficacy; randomized methods assessed separately. Original October/November 2011 report, not current access guidance. |
| NCI budget | Congressional appropriations through NIH/HHS. The dated page distinguishes enacted funding from requests; it does not allocate money to this disease page. | United States; NCI, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional. Institutional budget self-report, updated 14 May 2026; statutory scrutiny and an incentive to explain its public mission. |
| NCI Gift Fund and contributions | NCI accepts public donations through its Gift Fund; stamp-related public support is separate. No current disease-page donor ledger or corporate payment is established here. | United States; NCI, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional. Own contribution information, updated 27 August 2025; fundraising incentives. Donation authority does not prove a named donor funded a page. |
| NCI website editorial process | The website describes expert and editorial review. Its current public budget and gift routes are listed separately; the process page does not supply contributor contracts. | United States; NCI, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional. Own editorial-process account, reviewed 24 February 2025; institutional credibility incentives. Financial independence of underlying studies remains unknown. |
| NHS national website content policy | The dated national policy identifies DHSC funding and states no advertising or corporate sponsorship; it describes staff/contractor declarations. No individual provider finances are established. | England, United Kingdom; national website jurisdiction | Tier 3 — institutional financial/process self-report | B provisional for the dated self-report. Reviewed 14 October 2022; review due 14 October 2025 has passed. Later restructuring, page allocations and source-study ties are not cleared. |
| NCCIH FY2025 congressional justification | NIH/HHS federal budget route. This historical request is not an enacted current budget; the page explicitly says it no longer reflects current HHS policy. Gifts and page allocation remain unclosed. | United States; NCCIH, Bethesda, Maryland | Tier 3 — institutional financial/process self-report | B provisional for historical institutional self-report; budget-advocacy incentives. The proposal cannot establish present appropriations or supplement efficacy. |
| NCCIH: cancer and complementary approaches | See the historical NCCIH dated fiscal row; exact education-page allocation, expert interests, and each cited study’s finance are unresolved. | United States; NCCIH, Bethesda, Maryland | Tier 2 — public safety context; provisional | C provisional. Last updated October 2021, distinct from the website footer. Public safety education and institutional incentives; dated synthesis does not independently establish any product outcome. |
| CUH: FY2025–26 audited accounts | NHS commissioning, private/overseas care, research/training, charitable capital and other income; industry/academic partnerships. Exact IVF leaflet allocation unknown. | United Kingdom; NHS Foundation Trust, Cambridge | Tier 3 — financial self-report/statutory accounts | B provisional. Income notes 2.1–2.3 and partnership text read; care, commercial and budget incentives. |
| Novartis: 2025 annual financial/ownership report | Swiss Novartis AG owns significant operating subsidiaries. Medicines sales, equity and borrowing routes; shareholder/nominee interests. Exact Femara receipts and complete ultimate-beneficiary chain unclosed. | Switzerland; registered Novartis AG, Lichtstrasse 35, Basel; US label subsidiary separate | Tier 4 — seller-issued financial/ownership record; self-interest | B provisional for selected financial facts; D for independent efficacy. 2025 report published February 2026; investor/sales incentives. |
| NHSBSA: England 2025/26 PCA publication | Authority’s selected own finance below. Responsible statistician named Graham Platten; exact production allocation, personal declarations and contractor interests unclosed. | England dataset; United Kingdom authority, Newcastle upon Tyne | Tier 2 — public administrative statistics; provisional | B provisional. Published 4 June 2026, accredited official statistics. Public-accountability/service incentives; data-capture chain not fully audited here. |
| NHSBSA: June 2026 PCA methodology | See authority financial row below. Administrative reimbursement data; exact analytical contracts and complete underlying capture validation unclosed. | England community dispensing; United Kingdom authority | Tier 3 — institutional method/process self-report | B provisional. June 2026 methods; transparency and service incentives. Not disease-indication or patient-count evidence. |
| NHSBSA: 2025/26 chemical-substance table | See authority financial row below; no specific maker sponsorship established. Exact PCA allocation and complete data-capture audit unclosed. | England; national Chemical_Substances worksheet | Tier 2 — public administrative dataset; provisional | B provisional. 4 June 2026 release; reimbursement-based official counts, not a worldwide or cancer-only popularity ranking. |
| NHSBSA: 2025/26 audited institutional accounts | DHSC sponsor/appointed board; main Parliamentary support plus full-cost service-contract income and public repayment work. Separate student-support routes. Specific PCA allocation and staff/contractor interests unknown. | United Kingdom; Stella House, Goldcrest Way, Newcastle upon Tyne | Tier 3 — institutional financial/identity self-report | B provisional. Report printed 13 July 2026. Accountability/service incentives; selected notes read, complete subsidiary/backer audit unclosed. |
Frequently asked questions
Is letrozole chemotherapy? It is endocrine, or hormone, treatment rather than cytotoxic chemotherapy. NHS: letrozole overview.
Does every breast cancer respond to letrozole? Hormone-receptor results and the clinical setting determine whether endocrine treatment is relevant; a breast-cancer diagnosis alone is insufficient. NCI: breast-cancer biomarkers.
Can I stop letrozole because my joints hurt? Discuss symptoms and alternatives or an agreed break with your specialist; do not independently stop or restart it. NHS: taking and stopping letrozole.
Why is letrozole used for fertility if pregnancy is a concern? Fertility clinics may use a monitored course to induce ovulation. This differs from treatment during an established pregnancy; follow the specialist’s instructions. CUH: monitored letrozole ovulation induction.
Can I use HRT or a menopause supplement with letrozole? Discuss it with the prescribing team; NHS warns that such products may interfere with cancer treatment. NHS: letrozole interactions.
Do I need bone-density monitoring? The team determines your scan and bone-protection plan; no universal interval applies here. NHS: letrozole monitoring and treatment changes.
Sources and funding notes
Reviewed 4 October 2026. This is a dedicated letrozole medication guide, with a bounded fertility distinction. Source dates and provisional financial gaps remain explicit. The June 2026 label posting is distinct from its December 2024 prescribing-text revision. Manufacturer-financed or supplied efficacy is excluded from the independent verdict; safety warnings and licensed-care context retain separate roles. English administrative counts neither identify patients/indications nor rank worldwide cancer treatment. No personal tablet dose, fertility cycle, universal treatment duration or monitoring interval is supplied. Institutional revenues do not clear page contributors or original trials. Whole-source totals include linked prose, profiles/references, FAQs and repeated evidence/notes reserves.
- NHS: letrozole overview — Prescription tablet, brand and usual breast-cancer setting; broad prevention statement not treated as worldwide licensing.
- NHS: letrozole suitability — Allergy, menstrual status, pregnancy, organ disease and bone-health assessment; fertility indication distinguished.
- NHS: taking and stopping letrozole — Tablet handling, missed-dose safety and specialist-agreed changes; numerical dose/course not prescribed.
- NHS: letrozole adverse effects — Common symptoms and immediate versus urgent red flags; incidence and fixed scan schedules excluded.
- NHS: letrozole and reproduction — Urgent pregnancy discussion, breastfeeding and fertility-service distinction.
- NHS: letrozole interactions — HRT and menopause-product cautions, full medicine review; blanket compatibility not promised.
- NHS: letrozole monitoring and treatment changes — Bone/BP/cholesterol monitoring and agreed changes; copied medicine/mechanism errors excluded.
- NHS: osteoporosis assessment and nutrition — Fracture-risk and nutrition assessment only; general HRT advice not applied to letrozole users.
- NCI: letrozole drug summary — Aromatase activity and US breast-cancer indications; combination efficacy and promotional results excluded.
- NCI: breast-cancer hormone therapy — Premenopausal ovarian suppression and selected male advanced-cancer context; no independent efficacy estimate.
- NCI: breast-cancer biomarkers — ER/PR/HER2 distinctions and re-testing context; no individual response prediction.
- NCI: breast-cancer targeted therapy — Selected hormone/targeted combinations; no universal companion medicine or outcome claim.
- NCI: breast-cancer primary prevention — Primary risk reduction differs from recurrence care; US class licensing boundary, no prevention recommendation.
- NCI: hormone treatment and follow-up — Adjuvant/neoadjuvant purposes and clinical review; no fixed imaging schedule.
- NCI: sexual health during cancer care — Dryness, comfort and professional assessment; hormonal products require oncology review.
- NCI: fatigue assessment — Multiple contributing causes and tailored activity; supplement claims and numerical prevalence excluded.
- NCI: weight and eating problems — Nutrition assessment and dietitian support; no universal weight-loss prescription.
- NCI: clinical-trial participation — Eligibility, consent and uncertain benefit; no trial outcome adopted.
- NCI: research phases — Preclinical versus human safety/outcome evidence; no laboratory-derived human regimen.
- CUH: monitored letrozole ovulation induction — Explicit unlicensed ovulation-induction setting and monitoring only; all doses, cycle days and numerical pregnancy claims excluded.
- Novartis: dated Femara prescribing label — Pregnancy, liver, tamoxifen and animal cautions; doses/outcomes and outdated combination claim excluded.
- BIG 1-98: 2011 original trial and funding — Method and sponsor provenance only; all recurrence/survival estimates and comparative verdicts excluded.
- NCI budget — Institutional finance only; not treatment efficacy or author clearance.
- NCI Gift Fund and contributions — Additional institutional funding route and headquarters; no page allocation inferred.
- NCI website editorial process — Editorial process only; not an efficacy study.
- NHS national website content policy — National website funding/editorial policy, not hospital accounts or current author contracts.
- NCCIH FY2025 congressional justification — Dated institutional route only; no current expenditure total or private-gift exclusion.
- NCCIH: cancer and complementary approaches — Dated replacement/delay and supplement-interaction safety context; no independent product efficacy verdict.
- CUH: FY2025–26 audited accounts — Provider finance only; not current leaflet contributors’ or fertility-trial financial clearance.
- Novartis: 2025 annual financial/ownership report — Corporate finance and parent identity only; no product quality or clinical outcome inferred.
- NHSBSA: England 2025/26 PCA publication — Publication, scope and source link only; prescribing counts are not clinical outcomes.
- NHSBSA: June 2026 PCA methodology — Items and community scope, including hospital-issued/community-dispensed prescriptions; hospital-pharmacy dispensing excluded.
- NHSBSA: 2025/26 chemical-substance table — Letrozole item count only; costs, patient numbers and prescribing indications not inferred.
- NHSBSA: 2025/26 audited institutional accounts — Institutional finance only; no drug efficacy, item accuracy or maker influence inferred.
Educational research reviewed 4 October 2026. Diagnosis and treatment require a qualified clinician; this article does not provide an individual prescription or replace urgent assessment.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.